

POWERING AFFORDABLE CARE

with objective TB blood testing in 1 visit



TB blood testing is a convenient, efficient way to help protect patient health

Tuberculosis (TB) is one of the leading causes of infectious disease morbidity and mortality worldwide,¹ and reported cases have declined due to recent disruptions in routine TB control and prevention policies.²

20%

decline in reported **TB diagnoses in 2020** vs prepandemic levels²

13%

decline in reported **TB diagnoses in 2021** vs prepandemic levels²

Who should be tested for TB?

The CDC recommends that certain people be tested for TB infection.³



Those at higher risk for being infected:

- People who have spent time with someone who has TB disease
- People from a country where TB disease is common (most countries in Latin America, the Caribbean, Africa, Asia, Eastern Europe, and Russia)
- People who live or work in high-risk settings (eg, correctional facilities, long-term care facilities or nursing homes, and homeless shelters)
- Healthcare workers who care for patients at increased risk for TB disease
- Infants, children, and adolescents exposed to adults who are at increased risk for latent tuberculosis infection (LTBI) or TB disease



Those with a LTBI and who may be at higher risk for developing TB, including:

- People with HIV infection
- People who became infected with TB bacteria in the last 2 years
- Babies and young children
- People who inject illegal drugs
- People who are sick with other diseases that weaken the immune system
- Elderly people
- People who were not treated correctly for TB in the past



TB blood tests are more accurate than TB skin tests and provide a better patient experience

Traditional tuberculin skin tests (TSTs) are over a century old and feature some drawbacks compared to newer interferongamma release assay (IGRA) blood tests that are more convenient, reliable,⁴ and effective.⁵

	Blood test	TST
1 blood draw or testing appointment		×
Low false-positive rates compared to skin tests in individuals who received a Bacille Calmette-Guerin (BCG) vaccine ⁴		×
Objective results		×
Preferred by the CDC for certain patient populations ³		×
Not affected by the BCG vaccine		×
Cost savings and practice efficiency (1 blood draw vs multiple office visits, no follow-ups due to false positives, costs of missing LTBI)	V	×

Quest is the only lab that offers both TB blood tests approved by the FDA

The FDA has approved 2 IGRA blood tests: the QuantiFERON®-TB Gold Plus and T-SPOT®.*TB*.^a Either assay provides a more efficient process for TB testing as compared to TST tests.

T-SPOT®.TB

- 97.1% specificity [95% CI 94.5%-98.7%] in a US low-risk population⁶
- 95.6% sensitivity [95% CI 91.6%-98.1%] in culture-confirmed populations⁶
- Approved for immunocompromised patients
- Exclusive to Quest Diagnostics
- Results reported straight into an EHR system

QuantiFERON®-TB Gold Plus

- >97% specificity and >94% sensitivity⁷
- Innovative CD4+ and CD8+ T-cell technology delivers a more comprehensive evaluation of a patient's immune response to TB
- Results reported straight into an EHR system

^a Quest Diagnostics has validated the use of this assay under CLIA for processing specimens more than 8 hours after collection, up to 54 hours.



Visit **QuestDiagnostics.com/TB-HCP** to learn how Quest can help you optimize TB testing

The T-SPOT®.TB test is an in vitro diagnostic test for the detection of effector T cells that respond to stimulation by Mycobacterium tuberculosis antigens ESAT-6 and CFP-10 by capturing interferon gamma (IFN- γ) in the vicinity of T cells in human whole blood collected in sodium citrate or sodium or lithium heparin. It is intended for use as an aid in the diagnosis of M tuberculosis infection. The T-SPOT.TB test is an indirect test for M tuberculosis infection (including disease) and is intended for use in conjunction with risk assessment, radiography, and other medical and diagnostic evaluations.

Up-to-date relevant warnings, precautions, side effects, and contraindications can be found at: http://www.oxfordimmunotec.com/north-america/

QuantiFERON-TB Gold Plus. This test is a blood-based interferon-gamma release assay (IGRA) used as an aid in the diagnosis of *Mycobacterium tuberculosis* infection. It is an immune responsebased, indirect test for *M tuberculosis* infection (including disease) and is intended for use in conjunction with risk assessment, radiography, and other medical and diagnostic evaluations. Additional testing is needed to determine if a person who has tested positive has latent tuberculosis (TB) infection or TB disease.

This in vitro diagnostic test uses a peptide cocktail simulating ESAT-6, CFP-10, and TB7.7 proteins to stimulate cells in heparinized whole blood. Detection of interferon- γ (IFN- γ) by ELISA is used to identify in vitro responses to those peptide antigens that are associated with Mycobacterium tuberculosis infection.

References:

- 1. CDC. Tuberculosis. Published April 6, 2020. Accessed August 25, 2022. https://www.cdc.gov/globalhealth/newsroom/topics/tb/index.html
- 2. CDC. Effect of COVID-19 on TB in the United States. Updated March 24. 2022. Accessed August 29, 2022. https://www.cdc.gov/media/releases/2022/s0324-tuberculosis-covid-19.html
- CDC. Who should be tested for TB? Reviewed April 14, 2016. Accessed September 21, 2022. https://www.cdc.gov/tb/topic/testing/whobetested.htm
 CDC. Tuberculin skin testing fact sheet. Updated November 2, 2020. Accessed August 29, 2022. https://www.cdc.gov/tb/publications/factsheets/testing/skintesting.htm
- Construction skin testing fact sheets, oppated wovember 2, 2020. Accessed August 29, 2022. https://www.coc.gov/to/publications/lactsheets/testing/skintesting.htm
 Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention clinical practice guidelines: diagnosis of tubercules is adults and childran. *Olin Infect Dis* 2017;6/(2):111-115. doi:10.1093/cid/civ/278
- diagnosis of tuberculosis in adults and children. Clin. Infect. Dis. 2017;64(2):111-115. doi:10.1093/cid/ciw778 6. T-SPOT®. TB. Package Insert. Oxford Immunotec; 2022. Accessed October 24, 2022. https://www.tspot.com/wp-content/uploads/2022/10/TB-PI-US-0001-V10.pdf
- 7. Qiagen. TB testing with QFT-Plus. Accessed October 24, 2022. https://www.qiagen.com/us/applications/tb-management/products

Image content features a model and is intended for illustrative purposes only.

QuestDiagnostics.com

EN CROABLE CPR

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—[®] and TM—are the property of their respective owners. © 2022 Quest Diagnostics Incorporated. All rights reserved. SB11734 11/2022